Navigation Links
Concentric Named to List of Top 60 Healthcare Agencies in U.S.
Date:7/16/2008

Rankings Published by Medical Marketing & Media

NEW YORK, July 16 /PRNewswire/ -- Concentric Pharma Advertising, Inc., a five-year-old independent agency and one of the fastest growing in the field, has been ranked among the top 60 healthcare firms in the nation in Medical Marketing & Media's annual "Agency Issue" review, published this month.

The rankings, based on estimated revenue for 2007, place Concentric among some of the largest advertising networks in the U.S. and consolidate its position as a leading provider of integrated healthcare marketing services.

"We're visionary but also solidly pragmatic in our approach to marketing," said Ken Begasse Jr., chief operating officer of Concentric. "We develop novel, strategically sound creative ideas, then devote an uncommon amount of attention to proper execution, ensuring that the concepts are fully realized and can be accurately evaluated for effectiveness. This sustained attention to detail and to results has contributed significantly to our growth."

Concentric is one of the fastest growing agencies in the healthcare field, enjoying double-digit revenue growth for the fourth year in a row. In addition to expanding all existing client accounts and losing none, the agency won 10 new assignments in the past year, including accounts from Alcon Labs, Bayer HealthCare, Coria Laboratories, DePuy Spine, DePuy Mitek, Discovery Labs, Neuromed, and Wyeth.

Concentric also grew in terms of its service offerings and senior management team. Deepening its commitment to consumer education, the agency launched a new consumer division this past January under the leadership of Mike Devlin, executive vice president and managing director. Other senior appointments included Tim Campbell, senior vice president and director of account services; Ken Moran, senior vice president and director of operations; Adam Cohen, senior vice president and creative director; and Aimee Eastwood, senior vice
'/>"/>

SOURCE Concentric Pharma Advertising, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Concentric Medical Announces European Release of Expanded Family of Neurovascular Retrievers for use in Stroke Patients
2. Concentric Launches New Consumer Division, Names Mike Devlin EVP, Managing Director
3. Concentric Medical Names Kimberly Bridges as Vice President of Sales, Announces Receipt of $15 Million Growth Funding
4. Maria Sainz Named President and CEO of Concentric Medical
5. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
6. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
7. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
8. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
9. New Director of Nursing Practice Named for Nurses Association
10. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
11. Meeting Expectations Named to First Annual CMI 25 List by Corporate Meetings & Incentives Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...c. 4 Aurora Health Care is ramping...upplements. Aurora,s Care Management,Clinical Lea...e all Aurora,caregivers about the benefits of Vit...idence that higher Vitamin D levels may improve ou...sis, certain muscle conditions and,seasonal depre...
(Date:12/4/2008)...as, Dec. 4 MiddleBrook,...ounced that it has opened its,administrative and ...rmantown,facility will continue to house certain ...research and development group. The newly leased ...to house up to 60 employees as MiddleBrook,grows....
(Date:12/4/2008)...ch., Dec. 4 BAPTIST HEALTH, a six-...he state,s largest health system, has,expanded it... Reuters -- a,solution that enabled the system,s ...entions and save more than $1 million. , "D... campus show that,CareFocus prompts approximately...
(Date:12/4/2008)...similar to those seen with standard dose of daunor... (HealthDay News) -- A high dose of the chemothera...ts with previously untreated acute myeloid leukemi...by the U.S. National Cancer Institute (NCI) show. ... This study included 633 patients, aged 16 to 60, ...
Breaking Medicine News(10 mins):Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2
...ans for the Northeast have been announced by the H...is expected to be opened by 2015//. The five exis...d in Dundalk, Drogheda, Navan, Monaghan. and Cavan... Walsh at Monaghan General Hospital last year cons...
...Municipal Corporation’s (BMC) Health Committee had...d conducted health camps// Chamunda Nagar and Shya...on have been reported. Their report has concluded ...te survey conducted by an NGO, Bal Hakk Abhiyan (B...
...e July 15 issue of Clinical Infectious Diseases sa...s could be very useful// in the event of an influe...atins lower "bad" cholesterol levels in the blood ... cholesterol. Statins may further protect the hear...
...he medicos who had resorted to the strike against ...h Minister Anbumani Ramadoss today said that not p...as not a punishment. 'It is not a punitive action....elease the salaries, we will do so,' he told repor...
Other Medicine News:Health News:Children In Slums Of Mumbai Might be Suffering From Malnutrition 2Health News:Statins Could Play Important Role In Influenza Pandemic 2
(Date:12/3/2008)...3 Wyeth Pharmaceuticals,...day that it has submitted a,marketing authorizati...ncy,(EMEA) for approval to market its investigati...V13) for infants and young children. Wyeth is see...ccal disease (PD) caused by the 13,serotypes incl...
(Date:12/2/2008)...ire-USNewswire/ -- Researchers using functional,M...e area of the brain,responsible for suppressing m...,stress-related psychiatric disorders. Results of ...eeting of the Radiological Society of North Americ...ssion and other stress-related disorders,traumat...
(Date:12/2/2008)...Newswire/ -- Horizon Therapeutics, Inc., a,privat...d that two pivotal,Phase 3 trials evaluating its ...met all primary endpoints. HZT-501, a novel, propr...ibuprofen and famotidine, demonstrated a,statisti...n-steroidal,anti-inflammatory drug (NSAID)-induce...
(Date:12/1/2008)...swire/ -- TargeGen has announced that an oral,pre...ter, US-based clinical,trial of TG101348 in myelo...at,the 2008 American Society of Hematology (ASH) ...e as follows:, Title: A Phase I... JAK2-Selective Inhibitor, in Pat...
Breaking Medicine Technology:Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 1Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 2Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 3MRI Can Be Predictor of Post Treatment Prostate Cancer Spread 15095 1MRI Can Be Predictor of Post Treatment Prostate Cancer Spread 15095 2Mounting evidence shows red wine antioxidant kills cancer 2618 1Mounting evidence shows red wine antioxidant kills cancer 2618 2Mounting evidence shows red wine antioxidant kills cancer 2618 3New York City Staffing Company Charged With Violating H 1B Program Following U S Labor Department Finding Almost 243 Million in Back Wages Due 156 W 15090 1New York City Staffing Company Charged With Violating H 1B Program Following U S Labor Department Finding Almost 243 Million in Back Wages Due 156 W 15090 2
...ne Plus Minocycline Showed Substantial,Reduction o...ng-Remitting Multiple Sclerosis , Combination Trea...s and Was Well Tolerated , KANSAS CITY, Mo, May 4,...tudy showed that a combination of Copaxone,(glatir...otic,minocycline reduced T1 Gadolinium (Gd)-enhanc...
...th May 2007 - CeNeS Pharmaceuticals plc,(LSE: CEN)...otes,the publication of an independent study in th...hase II NMDA antagonist, CNS 5161. CeNeS,is develo...thic,pain. The independent study builds on the wor... , In the study reported in ,Synapse, Dr Anat Bie...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
Large solid mallet with patented Ortho-Grip® silicone rubber handle.
Angled ring curette.
Perisoteal rasp for elevating, dissecting, and scraping.
Stainless steel bone clamp.
Medicine Products: